High-density lipoproteins and atherosclerosis

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 62-70

  Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; FIBRIC ACID DERIVATIVE; GENE PRODUCT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; THIAZOLIDINE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; FLUSHING; HUMAN; INHIBITION KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; REVIEW; SIDE EFFECT;

EID: 0037126375     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02635-8     Document Type: Article

References (134)

1. Gordon D.J., Rifkind B.M. High-density lipoproteins - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
2. Genest J., Bard J.M., Fruchart J.C., Ordovas J.M., Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb Vasc Biol. 13:1993;1728-1737.
3. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
4. Reaven G.M., Chen Y.D.I., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 92:1993;141-146.
5. Rader D.J., Ikewaki K. Unraveling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
6. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1243.
7. Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., Sakai M., Hakamata H., Sakamoto Y., Naito M., et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 15:1995;1882-1888.
8. Rubin E., Krauss R., Spangler E., Verstuyft J., Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267.
9. Plump A., Scott C., Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 91:1994;9607-9611.
10. Paszty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 94:1994;899-903.
11. Liu A.C., Lawn R.M., Verstuyft J.G., Rubin E.M. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res. 35:1994;2263-2267.
12. Tangirala R.K., Tsukamoto K., Chun S.H., Usher D., Pure E., Rader D.J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 100:1999;1816-1822.
13. Benoit P., Emmanuel F., Caillaud J.M., Bassinet L., Castro G., Gallix P., Fruchart J.C., Branellec D., Denefle P., Duverger N. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation. 99:1999;105-110.
14. Duverger N., Kruth H., Emmanuel F., Caillaud J., Viglietta C., Castro G., Tailleux A., Fievet C., Fruchart J., Houdebine L.M., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 94:1996;713-717.
15. Ishiguro H., Yoshida H., Major A.S., Zhu T., Babaev V.R., Linton M.F., Fazio S. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J Biol Chem. 276:2001;36742-36748.
16. Li H., Reddick R., Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 13:1993;1814-1821.
17. Voyiaziakis E., Goldberg I.J., Plump A.S., Rubin E.M., Breslow J.L., Huang L.S. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 39:1998;313-321.
18. Hughes S.D., Verstuyft J., Rubin E.M. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb Vasc Biol. 17:1997;1725-1729.
19. Barter P.J., Rye K. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol. 7:1996;82-87.
20. Hobbs H.H., Rader D.J. ABC1 connecting yellow tonsils, neuropathy, and very low HDL . J Clin Invest. 104:1999;1015-1017.
21. McNeish J., Aiello R.J., Guyot D., Turi T., Gabel C., Aldinger C., Hoppe K.L., Roach M.L., Royer L.J., de Wet J., et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA. 97:2000;4245-4250.
22. Haghpassand M., Bourassa P.A., Francone O.L., Aiello R.J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest. 108:2001;1315-1320.
23. Vaisman B.L., Lambert G., Amar M., Joyce C., Ito T., Shamburek R.D., Cain W.J., Fruchart-Najib J., Neufeld E.D., Remaley A.T., et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 108:2001;303-309.
24. van Eck M., Bos I.S., Kaminski W.E., Orso E., Rothe G., Twisk J., Bottcher A., van Amersfoort E.S., Christiansen-Weber T.A., Fung-Leung W.P., et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA. 99:2002;6298-6303.
25. Aiello R.J., Brees D., Bourassa P.A., Royer L., Lindsey S., Coskran T., Haghpassand M., Francone O.L. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 22:2002;630-637.
26. Joyce C.W., Amar M.J., Lambert G., Vaisman B.L., Paigen B., Najib-Fruchart J., Hoyt R.F. Jr, Neufeld E.D., Remaley A.T., Fredrickson D.S., et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA. 99:2002;407-412.
27. Santamarina-Fojo S., Lambert G., Hoeg J.M., Brewer H.B. Jr. Lecithin-cholesterol acyltransferase role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis . Curr Opin Lipidol. 11:2000;267-275.
28. Vaisman B.L., Klein H.G., Rouis M., Berard A.M., Kindt M.R., Talley G.D., Meyn S.M., Hoyt R.F.J., Marcovina S.M., Albers J.J. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 270:1995;12269-12275.
29. Seguret-Mace S., Latta-Mahieu M., Castro G., Luc G., Fruchart J.C., Rubin E., Denefle P., Duverger N. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation. 94:1996;2177-2184.
30. Hoeg J., Vaisman B., Demosky S., Meyn S., Talley G., Hoyt R., Feldman S., Berard A., Sakai N., Wood D., et al. Lecithin cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits . J Biol Chem. 271:1996;4396-4402.
31. Francone O.L., Haghpassand M., Bennett J.A., Royer L., McNeish J. Expression of human lecithin: cholesterol acyltransferase in transgenic mice effects on cholesterol efflux, esterification, and transport . J Lipid Res. 38:1997;813-822.
32. Ng D.S., Francone O.L., Forte T.M., Zhang J., Haghpassand M., Rubin E.M. Disruption of the murine lecithin cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I . J Biol Chem. 272:1997;15777-15781.
33. Lambert G., Sakai N., Vaisman B.L., Neufeld E.B., Marteyn B., Chan C.C., Paigen B., Lupia E., Thomas A., Striker L.J., et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterolacyl transferase-deficient mice. J Biol Chem. 276:2001;15090-15098.
34. Hoeg J.M., Vaisman B.L., Demosky S.J. Jr, Meyn S.M., Talley G.D., Hoyt R.F. Jr, Feldman S., Berard A.M., Sakai N., Wood D., et al. Lecithin cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits . J Biol Chem. 271:1996;4396-4402.
35. Hoeg J.M., Santamarina-Fojo S., Berard A.M., Cornhill J.F., Herderick E.E., Feldman S.H., Haudenschild C.C., Vaisman B.L., Hoyt R.F. Jr, Demosky S.J. Jr, Kauffman R.D., Hazel C.M., Marcovina S.M., Brewer H.B. Jr, et al. Overexpression of lecithin cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis . Proc Natl Acad Sci U S A. 93:1996;11448-11453.
36. Brousseau M.E., Kauffman R.D., Herderick E.E., Demosky S.J. Jr, Evans W., Marcovina S., Santamarina-Fojo S., Brewer H.B. Jr, Hoeg J.M. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol. 20:2000;450-458.
37. Berard A.M., Foger B., Remaley A., Vaisman B.L., Talley G., Paigen B., Hoyt R.F., Brewer H.B.J., Santamarina-Fojo S. High plasma HDL concentration associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 3:1997;744-749.
38. Mehlum A., Gjernes E., Solberg L.A., Hagve T.A., Prydz H. Overexpression of human lecithin cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis . APMIS. 108:2000;336-342.
39. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., Fruchart-Najib J., Paiz J.A., Koch C.A., Hoyt R.F., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 274:1999;36912-36920.
40. Furbee J.W. Jr, Sawyer J.K., Parks J.S. Lecithin cholesterol acyltransferase (LCAT) deficiency increases atherosclerosis in the low density lipoprotein receptor (LDLr) or apolipoprotein E (apoE) knockout mice . J Biol Chem. 277:(5):2002;3511-3529.
41. Rigotti A., Trigatti B., Babitt J., Penman M., Xu S., Krieger M. Scavenger receptor BI - a cell surface receptor for high density lipoprotein. Curr Opin Lipidol. 8:1997;181-188.
42. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-B1 alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
43. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein apoB, low density lipoprotein apoB, and high density lipoprotein in transgenic mice. J Biol Chem. 273:1998;32920-32926.
44. Ueda Y., Royer L., Gong E., Zhang J., Cooper P.N., Francone O., Rubin E.M. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem. 274:1999;7165-7171.
45. Arai T., Wang N., Bezouevski M., Welch C., Tall A.R. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 274:1999;2366-2371.
46. Ueda Y., Gong E., Royer L., Cooper P.N., Francone O.L., Rubin E.M. Relationship between expression levels and atherogenesis in scavenger receptor class B, type 1 transgenics. J Biol Chem. 275:2000;20368-20373.
47. Kozarsky K.F., Donahee M.H., Glick J.M., Krieger M., Rader D.J. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 20:2000;721-727.
48. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key in HDL metabolism. Proc Natl Acad Sci U S A. 94:1997;12610-12615.
49. Varban M.L., Rinninger F., Wang N., Fairchild-Huntress V., Dunmore J.H., Fang O., Gosselin M.L., Dixon K.L., Deeds J.D., Acton S.L., et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 95:1998;4619-4624.
50. Trigatti B., Rayburn H., Vinals M., Braun A., Miettinen H., Penman M., Hertz M., Schrenzel M., Amigo L., Rigotti A., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A. 96:1999;9322-9327.
51. Braun A., Trigatti B.L., Post M.J., Sato K., Simons M., Edelberg J.M., Rosenberg R.D., Schrenzel M., Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 90:2002;270-276.
52. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
53. Schwartz C.C., Vlahcevic Z.R., Halloran L.G., Swell L. An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile. Biochem Biophys Acta. 663:1981;143-162.
54. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., Maruhama Y., Mabuchi H., Tall A.R. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 323:1990;1234-1238.
55. Moriyama Y., Okamura T., Inazu A., Doi M., Iso H., Mouri Y., Ishikawa Y., Suzuki H., Iida M., Koizumi J., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med. 27:1998;659-667.
56. Hirano K., Yamashita S., Kuga Y., Sakai N., Nozaki S., Kihara S., Arai T., Yanagi K., Takami S., Menju M., et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 15:1995;1849-1856.
57. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 97:1996;2687-2688.
58. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
59. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., Tall A.R. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 19:1999;1105-1110.
60. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., Tall A.R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 96:1995;2071-2074.
61. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
62. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112.
63. Bakkeren H.F., Kuipers F., Vonk R.J., Van Berkel T.J. Evidence for reverse cholesterol transport in vivo from liver endothelial cells to parenchymal cells and bile by high-density lipoprotein. Biochem J. 268:1990;685-691.
64. Stein O., Dabach Y., Hollander G., Ben Naim M., Halperin G., Stein Y. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis? Atherosclerosis. 144:1999;367-374.
65. Osono Y., Woollett L.A., Marotti K.R., Melchoir G.W., Dietschy J.M. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci U S A. 93:1996;4114-4119.
66. Jolley C.D., Woollett L.A., Turley S.D., Dietschy J.M. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 39:1998;2143-2149.
67. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I potential reverse cholesterol transport in humans . Circulation. 100:1999;594-598.
68. Alam K., Meidell R.S., Spady D.K. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem. 276:2001;15641-15649.
69. Groen A.K., Bloks V.W., Bandsma R.H., Ottenhoff R., Chimini G., Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest. 108:2001;843-850.
70. Tall A.R., Wang N., Mucksavage P. Is it time to modify the reverse cholesterol transport model? J Clin Invest. 108:2001;1273-1275.
71. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., Reddy S., Shih D., Shi W., Watson A.D., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 21:2001;481-488.
72. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis basic mechanisms. Oxidation, inflammation, and genetics . Circulation. 91:1995;2488-2496.
73. Sanguinetti S.M., Brites F.D., Fasulo V., Verona J., Elbert A., Wikinski R.L., Schreier L.E. HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diabetes Nutr Metab. 14:2001;27-36.
74. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein step 1 . J Lipid Res. 41:2000;1481-1494.
75. Navab M., Hama S.Y., Anantharamaiah G.M., Hassan K., Hough G.P., Watson A.D., Reddy S.T., Sevanian A., Fonarow G.C., Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein steps 2 and 3 . J Lipid Res. 41:2000;1495-1508.
76. Klimov A.N., Gurevich V.S., Nikiforova A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L., Teryukova N.P. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis. 100:1993;13-18.
77. Cockerill G., Rye K., Gamble J., Vadas M.A., Barter P.J. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 15:1995;1987-1994.
78. Cockerill G.W., Saklatvala J., Ridley S.H., Yarwood H., Miller N.E., Oral B., Nithyanathan S., Taylor G., Haskard D.O. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 19:1999;910-917.
79. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res. 40:1999;345-353.
80. Calabresi L., Franceschini G., Sirtori C.R., De Palma A., Saresella M., Ferrante P., Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 238:1997;61-65.
81. Ashby D., Gamble J., Vadas M., Fidge N., Siggins S., Rye K., Barter P.J. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis. 154:2001;113-121.
82. Ashby D.T., Rye K.A., Clay M.A., Vadas M.A., Gamble J.R., Barter P.J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;1450-1455.
83. Xia P., Vadas M.A., Rye K.A., Barter P.J., Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 274:1999;33143-33147.
84. Dimayuga P., Zhu J., Oguchi S., Chyu K.Y., Xu X.O., Yano J., Shah P.K., Nilsson J., Cercek B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun. 264:1999;465-468.
85. Stannard A.K., Khan S., Graham A., Owen J.S., Allen S.P. Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. Atherosclerosis. 154:2001;31-38.
86. Dansky H.M., Charlton S.A., Barlow C.B., Tamminen M., Smith J.D., Frank J.S., Breslow J.L. Apo A-I inhibits foam cell formation in apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest. 104:1999;31-39.
87. Vinals M., Martinez-Gonzalez J., Badimon J.J., Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (cox-2). Arterioscler Thromb Vasc Biol. 17:1997;3481-3488.
88. Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apo A-I). A novel function of apo A-I. J Clin Invest. 82:1988;803-807.
89. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G., Mendelsohn M.E., Hobbs H.H., Shaul P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 7:2001;853-857.
90. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., Fernandez J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 103:1999;219-227.
91. Griffin J.H., Fernandez J.A., Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost. 86:2001;386-394.
92. Eggerman T.L., Hoeg J.M., Meng M.S., Tombragel A., Bojanovski D., Brewer H.B. Jr. Differential tissue-specific expression of human apoA-I and apoA-II. J Lipid Res. 32:1991;821-828.
93. Rader D.J., Castro G., Zech L.A., Fruchart J.C., Brewer H.B. Jr. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J Lipid Res. 32:1991;1849-1859.
94. Mowri H.O., Patsch J.R., Gotto A.M. Jr, Patsch W. Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Arterioscler Thromb Vasc Biol. 16:1996;755-762.
95. Zhong S., Goldberg I.J., Bruce C., Rubin E., Breslow J.L., Tall A. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest. 94:1994;2457-2467.
96. Theret N., Delbart C., Aguie G., Fruchart J.C., Vassaux G., Ailhaud G. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation. Biochem Biophys Res Commun. 173:1990;1361-1368.
97. Schultz J.R., Verstuyft J.G., Gong E.L., Nichols A.V., Rubin E.M. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365:1993;762-764.
98. Remaley A.T., Stonik J.A., Demosky S.J., Neufeld E.B., Bocharov A.V., Vishnyakova T.G., Eggerman T.L., Patterson A., Duverger N.J., Santamarina-Fojo S., Brewer H.B.J.r. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 280:2001;818-823.
99. Duriez P., Fruchart J.C. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta. 286:1999;97-114.
100. Genest J.J. Jr, Bard J.M., Fruchart J.C., Ordovas J.M., Wilson P.F., Schaefer E.J. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 90:1991;149-157.
101. Vega G.L., Grundy S.M. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 7:1996;209-216.
102. Roheim P.S., Asztalos B.F. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem. 41:1995;147-152.
103. Rye K.A., Clay M.A., Barter P.J. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis. 145:1999;227-238.
104. Connelly P.W. The role of hepatic lipase in lipoprotein metabolism. Clin Chim Acta. 286:1999;243-255.
105. Fan J., Wang J., Bensadoun A., Lauer S.J., Dang Q., Mahley R.W., Taylor J.T. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci U S A. 91:1994;8724-8728.
106. Busch S.J., Barnhart R.L., Martin G.A., Fitzgerald M.D., Yates M.T., Mao S.J., Thomas C.E., Jackson R.L. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 269:1994;16376-16382.
107. Braschi S., Couture N., Gambarotta A., Gauthier B.R., Coffill C.R., Sparks D.L., Maeda N., Schultz J.R. Hepatic lipase affects both HDL and apoB-containing lipoprotein levels in the mouse. Biochem Biophys Res Commun. 1392:1998;276-290.
108. Homanics G.E., de Silva H.V., Osada J., Zhang S.H., Wong H., Borensztajn J., Maeda N. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem. 270:1995;2974-2980.
109. Mezdour H., Jones R., Dengremont C., Castro G., Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 272:1997;13570-13575.
110. Blades B., Vega G.L., Grundy S.M. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb Vasc Biol. 13:1993;1227-1235.
111. Katzel L.I., Coon P.J., Busby M.J., Gottlieb S.O., Krauss R.M., Goldberg A.P. Reduced HDL2 cholesterol subspecies and elevated postheparin hepatic lipase activity in older men with abdominal obesity and asymptomatic myocardial ischemia. Arterioscler Thromb. 12:1992;814-823.
112. Dugi K.A., Brandauer K., Schmidt N., Nau B., Schneider J.G., Mentz S., Keiper T., Schaefer J.R., Meissner C., Kather H., et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation. 104:2001;3057-3062.
113. Connelly P.W., Maguire G.F., Lee M., Little J.A. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis. 10:1990;40-48.
114. Hegele R., Little J.A., Vezina C., Maguire G., Tu L., Wolever T., Jenkins D., Connelly P. Hepatic lipase deficiency clinical, biochemical, and molecular genetic characteristics . Arterioscler Thromb. 13:1993;720-728.
115. Cohen J.C., Wang Z., Grundy S.M., Stoesz M.R., Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest. 94:1994;2377-2384.
116. Guerra R., Wang J., Grundy M.S., Cohen C.J. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 94:1997;4532-4537.
117. De Oliveira e Silva E.R., Kong M., Han Z., Starr C., Kass E.M., Juo S.H., Foster D., Dansky H.M., Merkel M., Cundey K., et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. J Lipid Res. 40:1999;1211-1221.
118. Hegele R.A., Harris S.B., Brunt J.H., Young T.K., Hanley A.J., Zinman B., Connelly P.W. Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis. 146:1999;153-160.
119. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase-mediated changes in LDL density . Circulation. 99:1999;1959-1964.
120. Jaye M., Lynch K.J., Krawiec J., Marchadier D., Maugeais C., Doan K., South V., Amin D., Perrone M., Rader D.J. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 21:1999;424-428.
121. Hirata K., Diechek H.L., Cioffi J.A., Choi S.Y., Leeper N.J., Quintana L., Kronmal G.S., Cooper A.D., Quertermous T. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 274:1999;14170-14175.
122. McCoy M.G., Sun G.S., Marchadier D., Maugeais C., Glick J.M., Rader D.J. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 43:2002;921-929.
123. Rader D.J., Jaye M. Endothelial lipase a new member of the triglyceride lipase gene family . Curr Opin Lipidol. 11:2000;141-147.
124. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
125. Thompson P.D., Rader D.J. Does exercise increase HDL cholesterol in those who need it the most? Arterioscler Thromb Vasc Biol. 21:2001;1097-1098.
126. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M.Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
127. Rader D.J., Haffner S.M. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol. 83:1999;30F-35F.
128. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
129. Patel J., Anderson R.J., Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes a twelve-week, randomized, placebo-controlled study . Diabetes Obes Metab. 1:1999;165-172.
130. Chilcott J., Tappenden P., Jones M.L., Wight J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 23:2001;1792-1823.
131. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedwald W. Fifteen year mortality in Coronary Drug Project patients long term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
132. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., Brody J. Efficacy and safety of an extended-release niacin (Niaspan) a long-term study . Am J Cardiol. 82:1998;74U-81U.
133. Guyton J.R., Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. [review] Am J Cardiol. 82:1998;82U-84U.
134. Wolfe M.L., Vartanian S.F., Ross J.L., Bansavich L.L., Mohler E.R. III, Meagher E., Friedrich C.A., Rader D.J. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 87:2001;476-499.